Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Resmed Inc (RMD)

Resmed Inc (RMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,087,718
  • Shares Outstanding, K 143,786
  • Annual Sales, $ 2,607 M
  • Annual Income, $ 404,590 K
  • 60-Month Beta 0.42
  • Price/Sales 8.87
  • Price/Cash Flow 34.10
  • Price/Book 10.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.01
  • Number of Estimates 4
  • High Estimate 1.03
  • Low Estimate 0.96
  • Prior Year 1.00
  • Growth Rate Est. (year over year) +1.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
153.12 +4.87%
on 01/03/20
161.98 -0.87%
on 01/17/20
+4.09 (+2.61%)
since 12/17/19
3-Month
126.26 +27.17%
on 10/23/19
161.98 -0.87%
on 01/17/20
+28.94 (+21.99%)
since 10/17/19
52-Week
90.64 +77.15%
on 01/29/19
161.98 -0.87%
on 01/17/20
+43.16 (+36.76%)
since 01/17/19

Most Recent Stories

More News
RESMED ALERT: Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of ResMed, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against certain officers and directors of ResMed, Inc. (NYSE: RMD) on behalf of long-term stockholders....

RMD : 160.57 (-0.10%)
Robbins LLP Is Investigating the Officers and Directors of ResMed Inc. (RMD) on Behalf of Shareholders

Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of ResMed Inc. (NYSE: RMD) breached their fiduciary duties to shareholders. ResMed develops, manufactures,...

RMD : 160.57 (-0.10%)
ResMed to Report Second Quarter Fiscal 2020 Earnings on January 30, 2020

ResMed (NYSE: RMD) (ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2020 on Thursday, January 30, 2020, after the New York Stock Exchange...

RMD : 160.57 (-0.10%)
SmarTrend Watching for Potential Pullback in Shares of Resmed Inc After 1.08% Gain

Resmed Inc (NYSE:RMD) traded in a range yesterday that spanned from a low of $157.01 to a high of $157.75. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $156.12...

RMD : 160.57 (-0.10%)
ResMed Announces Participation in the 38th Annual J.P. Morgan Healthcare Conference

ResMed (NYSE: RMD, ASX: RMD) today announced that Mick Farrell, chief executive officer, will present at the 38th Annual J.P. Morgan Annual Healthcare Conference on Monday, January 13, 2020, beginning...

JPM : 138.20 (+0.69%)
RMD : 160.57 (-0.10%)
NUVA vs. RMD: Which Stock Is the Better Value Option?

NUVA vs. RMD: Which Stock Is the Better Value Option?

NUVA : 78.10 (-1.59%)
RMD : 160.57 (-0.10%)
Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry

Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.

TNDM : 68.59 (-1.34%)
HAE : 113.85 (-1.86%)
RMD : 160.57 (-0.10%)
NUVA : 78.10 (-1.59%)
Product Launches Aid Intersect ENT (XENT) Despite Cost Woes

Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.

XENT : 24.45 (-1.93%)
RMD : 160.57 (-0.10%)
HAE : 113.85 (-1.86%)
EYE : 32.83 (+0.31%)
Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts

Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.

BRKR : 53.63 (-0.68%)
HAE : 113.85 (-1.86%)
RMD : 160.57 (-0.10%)
EYE : 32.83 (+0.31%)
Zimmer Biomet Hits New 52-Week High: What's Driving It?

Zimmer Biomet (ZBH) is optimistic about maintaining growth momentum on several recent positive developments.

HAE : 113.85 (-1.86%)
NUVA : 78.10 (-1.59%)
RMD : 160.57 (-0.10%)
ZBH : 149.38 (+0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade RMD with:

Business Summary

ResMed Inc. is a world-leading connected health company with cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions....

See More

Key Turning Points

2nd Resistance Point 162.67
1st Resistance Point 161.62
Last Price 160.57
1st Support Level 159.88
2nd Support Level 159.19

See More

52-Week High 161.98
Last Price 160.57
Fibonacci 61.8% 134.73
Fibonacci 50% 126.31
Fibonacci 38.2% 117.89
52-Week Low 90.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar